(MENAFNEditorial)
Despite the decline in oil prices impacting government spending we believe the Malaysian government will be able to maintain its commitment to the country ' s healthcare sector as it continues diversification of its revenue base. Moreover healthcare provision remains critical to the government which will limit reductions that affect medical services. However commercial opportunities for innovative drugmakers continue to be weighed down by low levels of intellectual property protection the implementation of a Goods and Service Tax (GST) as well as the preferential treatment of local drugmakers.
Headline Expenditure Projections
* Pharmaceuticals: MYR7.22bn (USD2.21bn) in 2014 to MYR7.88bn (USD2.13bn) in 2015; +9.2% in local currency and -3.4% in US dollar terms.
* Healthcare: MYR42.75bn (USD13.06bn) in 2014 to MYR46.13bn (USD12.47bn) in 2015; +7.9% in local currency and -4.6% in US dollar terms.
Full Report Details at
-
Risk/Reward Index
Malaysia's Pharmaceutical Risk/Reward Index (RRI) score for Q315 is 58.9 out of 100 making it the eighth most attractive pharmaceutical market in the Asia Pacific region. It posts above-average scores for every indicator.
Key Trends And Developments
May 2015
* A total of 16 health infrastructure improvement projects worth MYR2.3bn (USD644.7mn) will be implemented across the Malaysian state of Johor under the 11th Malaysia Plan (11th MP) reports Bernama. The proposal for the projects which includes the construction of the new Pasir Gudang hospital and Sultanah Aminah 2 hospital in Tampoi have been submitted to the Economic Planning Unit for consideration according to State Health and Environment Committee Chairman Ayub Rahmat. The construction of new hospitals and health clinics under the 11th MP will be carried out by a collaborative effort between the state government and the health ministry. The state government is also proposing to upgrade the Segamat hospital to a specialist hospital as well as building health clinics in Rengit...
The Malaysia Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysia pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Malaysia to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Malaysia.
* Assess the activities strategy and market position of your competitors using our company profiles (including SWOTs KPIs and latest activity) and competitive landscape tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
* Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).
* Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).
* Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
* Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).
* OTC Drug Market: OTC sales (USDbn & % of total sales).
* Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.